Literature DB >> 20545324

The N-terminal integrity is critical for the stability and biological functions of endostatin.

Yan Fu1, Yongzhang Luo.   

Abstract

Endostatin is an endogenous angiogenesis inhibitor, and amino acid residues H1, H3, H11, and D76 at its N-terminus coordinate with one zinc ion. Recombinant endostatin suffering from N-terminal truncations during Pichia pastoris expression was widely used in previous studies and generated inconsistent antitumor results. However, little attention was paid to the possible alteration on the stability and activity of endostatin caused by N-terminal truncations. In this study, N-terminally truncated forms of endostatin expressed by P. pastoris are identified as N-1, N-3, and N-4, in which one or two of the four zinc-binding residues are lost. The N-terminal truncation of the first amino acid residue (H) does not result in a significant change in the conformation, zinc-binding capacity, thermodynamic stability, or biological activity, while truncations of the first three amino acid residues (HSH) or the first four amino acid residues (HSHR) dramatically decrease the thermodynamic stability measured by urea-induced unfolding and biological activities of endostatin both in vitro and in vivo. Intriguingly, ZBP-endostatin with a short extra zinc-binding peptide (ZBP) engineered at the N-terminus exhibits a more tightly packed tertiary structure and increased thermodynamic stability and cooperativity against urea, with more potent antiendothelial and antitumor activities than the wild-type endostatin. These findings demonstrate that the N-terminal integrity is essential for the stability and biological functions of endostatin, which provides fundamental explanations for the inconsistent antitumor activities of endostatin in a variety of studies, including the different therapeutic efficacies of endostatin and ZBP-endostatin in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20545324     DOI: 10.1021/bi100489x

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Endostatin specifically targets both tumor blood vessels and lymphatic vessels.

Authors:  Wei Zhuo; Yang Chen; Xiaomin Song; Yongzhang Luo
Journal:  Front Med       Date:  2011-12-27       Impact factor: 4.592

2.  Pharmacokinetics of PEGylated recombinant human endostatin (M2ES) in rats.

Authors:  Zuo-gang Li; Lin Jia; Li-fang Guo; Min Yu; Xu Sun; Wen Nie; Yan Fu; Chun-ming Rao; Jun-zhi Wang; Yong-zhang Luo
Journal:  Acta Pharmacol Sin       Date:  2015-06-01       Impact factor: 6.150

Review 3.  Endostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.

Authors:  Amit Walia; Jessica F Yang; Yu-Hui Huang; Mark I Rosenblatt; Jin-Hong Chang; Dimitri T Azar
Journal:  Biochim Biophys Acta       Date:  2015-09-12

4.  Stabilization by fusion to the C-terminus of hyperthermophile Sulfolobus tokodaii RNase HI: a possibility of protein stabilization tag.

Authors:  Kazufumi Takano; Tomohiro Okamoto; Jun Okada; Shun-ichi Tanaka; Clement Angkawidjaja; Yuichi Koga; Shigenori Kanaya
Journal:  PLoS One       Date:  2011-01-19       Impact factor: 3.240

5.  Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.

Authors:  Wen-guo Jiang; Xin-an Lu; Bo-yang Shang; Yan Fu; Sheng-hua Zhang; Daifu Zhou; Liang Li; Yi Li; Yongzhang Luo; Yong-su Zhen
Journal:  BMC Cancer       Date:  2013-10-15       Impact factor: 4.430

6.  E-M, an Engineered Endostatin with High ATPase Activity, Inhibits the Recruitment and Alternative Activation of Macrophages in Non-small Cell Lung Cancer.

Authors:  Min Xu; Shaosen Zhang; Lin Jia; Shan Wang; Jie Liu; Xuhui Ma; Chunying Wang; Yan Fu; Yongzhang Luo
Journal:  Front Pharmacol       Date:  2017-08-09       Impact factor: 5.810

7.  Validation of an enzyme-linked immunosorbent assay (ELISA) for quantification of endostatin levels in mice as a biomarker of developing glomerulonephritis.

Authors:  Jacqueline Wallwitz; Petra Aigner; Elisabeth Gadermaier; Eva Bauer; Emilio Casanova; Anton Bauer; Dagmar Stoiber
Journal:  PLoS One       Date:  2019-08-12       Impact factor: 3.240

8.  Oxidants, antioxidants and the current incurability of metastatic cancers.

Authors:  Jim Watson
Journal:  Open Biol       Date:  2013-01-08       Impact factor: 6.411

9.  Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog.

Authors:  Shan Wang; Yan Fu; Yongzhang Luo
Journal:  Chin J Cancer       Date:  2016-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.